Comparative study of efficacy, safety and cost effectiveness of topical Clindamycin 1% - Adapalene 0.1% combination therapy with oral doxycycline versus topical Benzoyl peroxide 2.5% - Adapalene 0.1% combination therapy with oral doxycycline in case of moderate to severe facial acne vulgaris: A prospective, randomised, open label parallel studyâ€.
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Efficacy and safety assessed from baseline at 4 and 8 weeks
研究概览
简要总结
Acne vulgaris is a disorder of the pilosebaceous unit that primarily affects adolescents. Cutibacterium acnes(formerly known as P.acnes) which is a commensal bacterium of the cutaneous microbiome playing a crucial role in acne development.Acne is the most common skin disease of adolescence, affecting over 80% of teenagers (aged 13-18 years) at some point. Classically, the pathogenesis of acne has been linked to four key processes viz increased sebum production,alteration of follicular keratinization leading to comedone formation,colonization of the follicle by Cutibacterium acnes,inflammation of pilosebaceous unit. Primary acne lesions include micro-comedones, comedones, papules,pustules,nodules & cysts.Secondary acne lesions include macular erythema, macular pigmentation,atrophic scars & hypertrophic/ keloidal scars. Benzoyl peroxide (BPO) is an effective antimicrobial (bactericidal) & anti-inflammatory and has rapid action, destroying both surface and ductal P. acnes & also possesses mild comedolytic property.Clindamycin is a lincosamide antibiotic and has antibacterial and anti-inflammatory properties.Adapalene being a third-generation retinoid has comedolytic and anti-inflammatory properties.Second-generation tetracyclines– doxycycline,lymecycline and minocycline–are widely recognized as the first oral antibiotic of choice for the treatment of acne.Doxycycline is a lipophilic tetracycline derivative with demonstrated efficacy in the treatment of inflammatory acne.It is available in doses of 50, 75,100 and 150mg;The most frequently prescribed dose for acne is 100mg.Common adverse effects associated with the use of this combination therapy includes Dry skin, irritative contact dermatitis, skin irritation, skin burning sensation, erythema, skin exfoliation.Based on several studies done across the globe regarding the topical combination therapy used in acne vulgaris, some are effective in decreasing the lesions with well tolerability & none of them proved to be helpful in complete recovery of patients.Hence, this study will be conducted to compare the efficacy, safety and cost effectiveness in moderate to severe facial acne vulgaris.A total of 60 patients visiting skin OPD based on eligibility with inclusion criteria,
1
subjects of either gender and subjects of 12 to 30 years of age with moderate to severe facial acne vulgaris having ≥ 19 and ≤38 score based on global acne grading system and after that written informed consent /assent from the subjects will be taken and only then the participants are allowed for a prospective, randomised, open label parallel study for duration of one and a half year at AIIMS Nagpur,will be conducted and Patients will be randomized using computer generated random number table either to receive topical Clindamycin 1% - Adapalene 0.1% combination therapy(0.5 grams applied at night) with oral doxycycline 100mg twice a day or topical Benzoyl peroxide 2.5% - Adapalene 0.1% combination therapy(0.5 grams applied at night)with oral doxycycline 100mg twice a day for 8 weeks and will be followed up at week 4 and 8 and their primary outcomes will be the change in GAGS score from baseline at the end of 8 weeks will be measured by statistical analysis in both groups
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Open Label
入排标准
- 年龄范围
- 12.00 Year(s) 至 30.00 Year(s)(—)
- 性别
- All
入选标准
- •Subjects of either gender.
- •Subjects of 12 to 30 years of age with moderate to severe facial acne vulgaris having ≥ 19 and ≤38 score based on global acne grading system.
排除标准
- •Patients already on anti-acne medication(topical or oral) in last one month.
- •Patients having nodulocystic lesions, acne conglobata, acne fulminans, secondary acne.
- •Patients unwilling to give written informed consent.
- •Patients with known hypersensitivity to benzoyl peroxide, clindamycin or adapalene and doxycycline.
- •Pregnant or lactating women.
结局指标
主要结局
Efficacy and safety assessed from baseline at 4 and 8 weeks
时间窗: From baseline at the end of 4 and 8 weeks,
cost effectiveness assessed at 8 weeks
时间窗: From baseline at the end of 4 and 8 weeks,
次要结局
- Adverse event(cost effectiveness evaluated)
